Abbott Labs Earnings, Revenue Beat in Q4 By Investing.com

Investing.com – Abbott Labs (NYSE:) reported on Wednesday fourth quarter that beat analysts’ forecasts and revenue that topped expectations.

Abbott Labs announced earnings per share of $1.45 on revenue of $10.70B. Analysts polled by Investing.com anticipated EPS of $1.35 on revenue of $9.94B.

Abbott Labs shares are down 5% from the beginning of the year, still down 0.58% from its 52 week high of $115.40 set on January 25. They are under-performing the S&P 500 which is up 2.49% from the start of the year.

Abbott Labs shares gained 2.74% in pre-market trade following the report.

Abbott Labs follows other major Healthcare sector earnings this month

Abbott Labs’s report follows an earnings beat by J&J on Tuesday, who reported EPS of $1.86 on revenue of $22.48B, compared to forecasts EPS of $1.83 on revenue of $21.69B.

Novartis ADR had missed expectations on Tuesday with fourth quarter EPS of $1.34 on revenue of $12.77B, compared to forecast for EPS of $1.36 on revenue of $12.92B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*